Glutathione

Glutathione

SCHEMBL7469803

N[C@@H](CCC(=O)N[C@H](CS)C(=O)NCC(=O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 1.00
GSTK1 Q9Y2Q3 1/20 1.00
GLO1 Q04760 2/20 0.65
NOD1 Q9Y239 7/20 0.46
FOLH1 Q04609 2/20 0.43
GRM8 O00222 1/20 0.43
GRM6 O15303 1/20 0.43
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GSR P00390 1/20 0.43
CYP1A2 P05177 1/20 0.43
GRIK1 P39086 1/20 0.43
GRM5 P41594 1/20 0.43
GRIA1 P42261 1/20 0.43
GRIA2 P42262 1/20 0.43
GRIA3 P42263 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
GRIA4 P48058 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutathione SCHEMBL28505216 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL14364095 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL272141 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL5167025 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL5167030 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL13105609 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL9167 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL15701576 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL1105665 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1
Glutathione SCHEMBL30733475 1.00 PTGS1 (1.00) PTGS1GSTK1GLO1NOD1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156826-A1 METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONIST LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2024-05-16 US disclosed
CN-117871699-A Application of group of markers in detection of oxaliplatin adverse reaction 李鸿雁 2024-04-12 CN disclosed
WO-2023223223-A1 A PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR REDUCING HEPATOTOXICITY INDUCED BY ACETAMINOPHEN APTYS PHARMACEUTICALS SAS (FR) 2023-11-23 WO disclosed
US-11806353-B2 Methods of treating liver disorders or lipid disorders with a THR-beta agonist MADRIGAL PHARMACEUTICALS, INC. (US) 2023-11-07 US disclosed
EP-4112056-A1 METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONIST Madrigal Pharmaceuticals, Inc. (US) 2023-01-04 EP disclosed
WO-2018089481-A1 MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF MALLINCKRODT LLC (US) 2018-05-17 WO disclosed
US-20140121100-A1 COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH NOVOZYMES BIOAG A/S (DK) 2014-05-01 US disclosed
CN-102103141-B Immunity-chromatography kit for rapid diagnosis of malaria and its pathogen species and preparation method thereof NAT INST OF PARASITIC DISEASE CHINESE CT FOR DISEASE CONTROL AND PREVENTION 2014-04-09 CN disclosed
CN-102103141-A Immunity-chromatography kit for rapid diagnosis of malaria and its pathogen species and preparation method thereof NAT INST OF PARASITIC DISEASE CHINESE CT FOR DISEASE CONTROL AND PREVENTION 2011-06-22 CN disclosed
US-20070269375-A1 Stable Radiopharmaceutical Compositions and Methods for Preparation BRACCO IMAGING S.P.A. (IT) 2007-11-22 US disclosed
WO-2002029103-A2 GENE EXPRESSION PROFILES IN LIVER CANCER GENE LOGIC, INC. (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156826-A1 METHODS OF TREATING LIVER DISORDERS OR LIPID DISORDERS WITH A THR-BETA AGONIST THRB, THRA, CPT1A PTGS1 1854/4885GSTK1 791/4885GLO1 1246/4885
US-20070269375-A1 Stable Radiopharmaceutical Compositions and Methods for Preparation GRPR, GIPR, SSTR3 PTGS1 4001/4885GSTK1 3661/4885GLO1 2938/4885
US-11806353-B2 Methods of treating liver disorders or lipid disorders with a THR-beta agonist THRB, THRA, CPT1A PTGS1 1854/4885GSTK1 791/4885GLO1 1246/4885
US-20140121100-A1 COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH GSS, GSTO1, GSTA1 PTGS1 111/4885GSTK1 23/4885GLO1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.